Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?
(2017)
Report
Price, L., & Brunt, A. M. (2017). Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?
Trastuzumab (Herceptin) is used in neoadjuvant, adjuvant and metastatic breast cancer. Infusion reactions are a common side effect most of which are mild and easily managed, anaphylaxis occurs rarely. The summary of product characteristics recommends... Read More about Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?.